Yes, Akebia Therapeutics successfully achieved a major regulatory milestone with the United States Food and Drug Administration (FDA) granting approval for Vafseo (vadadustat) tablets, an oral treatment designed for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. This flagship approval marked a transformative turning point for the enterprise, transitioning it from a purely developmental-stage research firm into a commercial-stage biopharmaceutical organization. The company manages the ongoing commercialization, distribution, and physician outreach for Vafseo while continuing to evaluate additional clinical pipeline indications for its therapeutic compounds.